Studies Implemented by Hospital dos Servidores Rio de Janeiro
| Study Number | Study Title | Study Status | Study Restriction |
|---|---|---|---|
|
(11954) |
Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study |
Enrolling |
US & Non-US |
|
(11891) |
A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-1 Exposed Infants at High Risk |
Enrolling |
US & Non-US |
|
(11790) |
Raltegravir Pharmacokinetics and Safety in Neonates |
Closed to Follow Up |
United States |
|
(11773) |
Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents |
Enrolling |
US & Non-US |
|
(10850) |
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral Experienced HIV-1 Infected Infants and Children, Aged >= 2 Months to < 6 Years |
Closed to Accrual |
US & Non-US |
|
(10787) |
A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines |
Participants Off Study and Primary Analysis Completed |
US & Non-US |
|
(10495) |
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Raltegravir (Isentress™, MK-0518) in HIV-1 Infected Children and Adolescents |
Participants Off Study and Primary Analysis Completed |
US & Non-US |
|
(10040) |
Pharmacokinetic Properties of Antiretroviral Therapy during Pregnancy |
Enrolling |
US & Non-US |
|
(30129) |
Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants |
Closed to Accrual |
US & Non-US |
|
(20735) |
Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants |
Enrolling |
US & Non-US |
HPTN 057 (10143) |
Phase I Open Label Trial of the Safety and Pharmacokinetics of Tenofovir Disoproxil Fumarate in HIV-1 Infected Pregnant Women and their Infants |
Concluded |
Not Applicable |
|
(10779) |
HAART Standard Version of the PROMISE Study: Promoting Maternal and Infant Survival Everywhere |
Participants Off Study and Primary Analysis Completed |
US & Non-US |